StockData
Pasithea Therapeutics Corp. logo

Pasithea Therapeutics Corp. (KTTA) stock

KTTANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.43−0.07 (-13.14%)

Close on Nov 17, 2026Market cap $14.51MP/E –Yield –

Pasithea Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2022 it was 76.7%, against -14.7% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2022Dec 31, 202276.7%+91.4
FY2021Dec 31, 2021-14.7%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2022Sep 30, 202260.4%–
Q2 FY2022Jun 30, 2022-11.2%–
Q1 FY2022Mar 31, 20225.3%–

More Pasithea Therapeutics figures

See a number that looks wrong?